AIM ImmunoTech (AIM) Construction in Progress (2010 - 2014)
AIM ImmunoTech's (AIM) quarterly Construction in Progress came in at $7.3 million in Q4 2014, up 4.13% YoY from $7.0 million in Q4 2013, and up 0.94% on a QoQ basis from $7.3 million in Q3 2014.
AIM ImmunoTech (AIM) Construction in Progress (2010 - 2014) Analysis & Trends
AIM ImmunoTech (AIM) has 5 years of Construction in Progress data on file, last reported at $7.3 million in Q4 2014.
- Quarterly Construction in Progress rose 4.13% year-over-year to $7.3 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $7.3 million (up 4.13% YoY) and the FY2014 annual result came in at $7.3 million, up 4.13% from the prior year.
- Construction in Progress grew to $7.3 million in Q4 2014, from $7.3 million in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $7.3 million in Q4 2014 to a low of $485000.0 in Q4 2010.
- A 5-year average of $5.0 million and a median of $6.7 million in 2012 frame the typical range for Construction in Progress.
- Annual changes were most pronounced in 2012 — Construction in Progress jumped 442.02% — and 2014, when it rose 1.74%.
- Tracing AIM's Construction in Progress over 5 years: stood at $485000.0 in 2010, then jumped by 205.98% to $1.5 million in 2011, then surged by 343.4% to $6.6 million in 2012, then climbed by 7.08% to $7.0 million in 2013, then increased by 4.13% to $7.3 million in 2014.
- The last three Construction in Progress figures came in at $7.3 million (Q4 2014), $7.3 million (Q3 2014), and $7.2 million (Q2 2014), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 152.67 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 7.34 Mn |
| Sep 30, 2014 | 7.27 Mn |
| Jun 30, 2014 | 7.19 Mn |
| Mar 31, 2014 | 7.11 Mn |
| Dec 31, 2013 | 7.05 Mn |
| Sep 30, 2013 | 6.97 Mn |
| Jun 30, 2013 | 7.07 Mn |
| Mar 31, 2013 | 6.81 Mn |
| Dec 31, 2012 | 6.58 Mn |
| Sep 30, 2012 | 5.79 Mn |
| Jun 30, 2012 | 4.35 Mn |
| Mar 31, 2012 | 3.03 Mn |
| Dec 31, 2011 | 1.48 Mn |
| Sep 30, 2011 | 1.21 Mn |
| Jun 30, 2011 | 802,000.00 |
| Dec 31, 2010 | 485,000.00 |